← All Nanonews

Whole-genome sequencing of Leishmania infantum isolates to identify biomarkers of pathogenicity and drug resistance

Leishmania 1 April 2022

Copy-number profiles across Leishmania infantum chromosomes
Loading a nanopore sequencer

Nano1Health is sequencing the complete genomes of Leishmania infantum isolates from several Mediterranean countries, to characterise structural variants that can serve as biomarkers of pathogenicity and drug resistance.

Current diagnosis only shows whether the parasite is present; there are no biomarkers to predict pathogenicity or response to treatment. With about 2.5 million dogs diagnosed each year in Spain, France, Portugal and Italy, more pathogenic and drug-resistant strains are a One Health threat.

We use long-read sequencing and our own bioinformatics platform to characterise known and new structural variants. The work is part of a NEOTEC project funded by CDTI.

Questions about this news? Write to info@nano1health.com.